Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study

Moderna on Monday unveiled Phase III data for its investigational combination vaccine mRNA-1083, which demonstrated a superior immune response against COVID-19 and influenza compared to licensed vaccines.